Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
A therapeutic perspective of HDAC8 in different diseases: an overview of selective inhibitors
Histone deacetylases (HDACs) are epigenetic enzymes which participate in transcriptional
repression and chromatin condensation mechanisms by removing the acetyl moiety from …
repression and chromatin condensation mechanisms by removing the acetyl moiety from …
DNA repair inhibitors: potential targets and partners for targeted radionuclide therapy
H Obata, M Ogawa, MR Zalutsky - Pharmaceutics, 2023 - mdpi.com
The present review aims to explore the potential targets/partners for future targeted
radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively …
radionuclide therapy (TRT) strategies, wherein cancer cells often are not killed effectively …
DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway
S Ding, Y Gao, D Lv, Y Tao, S Liu, C Chen, Z Huang… - …, 2022 - thelancet.com
Background Distant metastasis remains the leading cause of treatment failure in patients
with nasopharyngeal carcinoma (NPC), making it critical to identify efficient therapeutic …
with nasopharyngeal carcinoma (NPC), making it critical to identify efficient therapeutic …
A Chemical Approach to Assess the Impact of Post-Translational Modification on MHC Peptide Binding and Effector Cell Engagement
JJ Kelly, N Bloodworth, Q Shao… - ACS Chemical …, 2024 - ACS Publications
The human major histocompatibility complex (MHC) plays a pivotal role in the presentation
of peptidic fragments from proteins, which can originate from self-proteins or from nonhuman …
of peptidic fragments from proteins, which can originate from self-proteins or from nonhuman …
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
P Zhang, Y Du, H Bai, Z Wang, J Duan, X Wang… - BMC medicine, 2022 - Springer
Background Although immune checkpoint inhibitors (ICIs) have influenced the treatment
paradigm for multiple solid tumors, increasing evidence suggests that primary and adaptive …
paradigm for multiple solid tumors, increasing evidence suggests that primary and adaptive …
Plant-derived sulforaphane suppresses growth and proliferation of drug-sensitive and drug-resistant bladder cancer cell lines in vitro
H **e, J Rutz, S Maxeiner, T Grein, A Thomas… - Cancers, 2022 - mdpi.com
Simple Summary The natural compound sulforaphane is highly popular among tumor
patients, since it is suggested to prevent oncogenesis and cancer progression. However …
patients, since it is suggested to prevent oncogenesis and cancer progression. However …
BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma
Q Zhu, X Gu, W Wei, Z Wu, F Gong, X Dong - Cancer Medicine, 2023 - Wiley Online Library
Background The intensive interplay between aberrant epigenetic events and metabolic
remodeling represents one of the hallmarks of tumors, including colon cancer. The functions …
remodeling represents one of the hallmarks of tumors, including colon cancer. The functions …
The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic …
X Li, S Tian, H Shi, N Ta, X Ni, C Bai, Z Zhu… - Cancer Gene …, 2024 - nature.com
SMARCA4-deficient undifferentiated thoracic tumor is extremely invasive. This tumor with
poor prognosis is easily confused with SMARCA4-deficent non-small cell lung cancer or …
poor prognosis is easily confused with SMARCA4-deficent non-small cell lung cancer or …
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-
stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with …
stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with …